Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: Results from ASSURE, ECOG 2805

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4048-4054

  Haas, Naomi B ^a   Manola, Judith ^b   Ky, Bonnie ^a   Flaherty, Keith T ^a   Uzzo, Robert G ^c   Kane, Christopher J ^d   Jewett, Michael ^e   Wood, Lori ^f   Wood, Christopher G ^g   Atkins, Michael B ^h   Dutcher, Janice J ⁱ   Wilding, George ^j   DiPaola, Robert S ^k  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ NEW YORK MEDICAL COLLEGE   (United States)

^j UNIVERSITY OF WISCONSIN   (United States)

^k RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY CARCINOMA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTIVE CARDIOMYOPATHY; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84942935858     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0215     Document Type: Article

References (25)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
2. Miller K, Wang M, Gralow J., Dickler M, Cobleigh M, Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
3. Llovet JM, Ricci S, Mazzaferro V., Hilgard P, Gane E, Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
4. Leboulleux S, Bastholt L, Krause T., de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13: 897-905.
5. Aghajanian C, Blank SV, Goff B.A., Judson PL, Teneriello MG, Husain A, et al OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30: 2039-45.
6. Escudier B, Eisen T, Stadler W.M., Szczylik C., Oudard S, Siebels M, et al Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 2007; 356:125-34.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson M.D., Bukowski RM, Oudard S, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
8. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-44.
9. Khakoo AY, Kassiotis CM, Tannir N, Plana J.C., Halushka M., Bickford C, et al. Heart failure associated with sunitinib maleate. Cancer 2008; 26: 5204-12.
10. Telli ML, Witteles RM, Fisher G.A., Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19:1613-8.
11. Chu TF, Rupnick MA, Kerkela R, Dallabrida S.M., Zurakowski D., Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-9.
12. Richards CJ, Je Y, Schutz F.A., Heng DY, Dallabrida SM, Moslehi JJ, et al Incidence and risk of congestive heart failure in patients with renal and non-renal cell carcinoma treated with sunitinib. J Clin Oncol 2011; 29: 3450-6.
13. Schmidinger M, Zielinski CC, Vogl U.M., Bojic A., Bojic M, Schukro C, et al Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-12.
14. Yancy CW, Jessup M, Bozkurt B., Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239.
15. Sutent (sunitinib maleate) capsules [package insert]. New York, NY: Pfizer Labs; 2008.
16. Nexavar (sorafenib)tablets [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc; 2008.
17. https://clinicaltrials.gov/ct2/show/NCT00326898 [cited 2014 Oct 15].
18. Motzer RJ, Rini BI, Bukowski R.M., Curti BD, George DJ, Hudes GR, et al Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-24
19. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-9.
20. Cardinale D, Colombo A, Sandri M.T., Lamantia G., Colombo N, Civelli M, et al Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-81.
21. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
22. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010; 28: 3422-8.
23. Seidman A, Hudis C, Pierri M.K., Shak S., Paton V, Ashby M, et al Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
24. Slamon D, Eiermann W, Robert N., Pienkowski T, Martin M, Press M., et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83.
25. Hall PS, Harshman LC, Srinivas S, Witteles RM The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013; 1: 72-8.